The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

Phase 2 Completed 38 enrolled ThromboGenics

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)

Timeline

Start: 2010-07
Primary completion: 2010-11
Completion: 2011-01

Publications

Stalmans P, Girach A. Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci. 2013 Oct 9;54(10):6620-7. doi: 10.1167/iovs.13-11811.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ocriplasmin	Protein / enzyme biologic	125 ug	Intravitreal

Indications

No indication recorded.